



Supplemental Figures for:  
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-line Therapy in Patients With Recurrent/Metastatic Head and Neck Cancer  
Maura L Gillison et al.

Supplemental Figure 1. CONSORT diagram.



Abbreviations: R/M, recurrent or metastatic; SCCHN, squamous cell carcinoma of the head and neck.

**Supplemental Figure 2.** Treatment effect on overall survival by subgroup for the overall intent-to-treat population.



<sup>a</sup>Stratification factor.

Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HPV, human papillomavirus; HR, hazard ratio; IC, investigator's choice; Nivo, nivolumab.